

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb60545</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Expression of the Hepatitis C Virus core-NS3 Fusion Protein on the Surface of  Bacterial Ghosts: Prospects for Vaccine Production</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Tayebinia </surname><given-names>Minoosadat</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sharifzadeh </surname><given-names>Sedigheh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rafiei Dehbidi </surname><given-names>Gholamreza</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Zare</surname><given-names>Farahnaz</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ranjbaran</surname><given-names>Reza</given-names></name></contrib><aff>Department of Anatomy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rahimi</surname><given-names>Amir</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Miri</surname><given-names>Mohammad Reza</given-names></name></contrib><aff>Department of Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mirzakhani </surname><given-names>Mehdi</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Behzad-Behbahani</surname><given-names>Abbas</given-names></name></contrib><aff>Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>15</volume>
      <issue>3</issue>
      <fpage>173</fpage>
      <lpage>179</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>12</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Background: Antigen presentation using bacterial surface display systems, on one hand, has the benefits of bacterial carriers, including low-cost production and ease of manipulation. On the other hand, the bacteria can help in stimulating the immune system as an adjuvant. For example, using bacterial surface display technology, we developed a hepatitis C virus (HCV) multiple antigens displaying bacteria&amp;#39;s surface and then turned it into a bacterial ghost.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Methods: The HCV core and NS3 proteins&amp;#39; conserved epitopes were cloned into the AIDA gene plasmid as an auto transporter. The recombinant plasmid was then transformed into Escherichia coli (E. coli) Bl21 (DE3). Recombinant bacteria were then turned into a bacterial ghost, an empty cell envelope. Whole-cell ELISA, flow cytometry, and Western blot techniques were used for monitoring the expression of proteins on the surface of bacteria.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Results: A fusion protein of HCV core-NS3-AIDA was successfully expressed on the E. coli Bl21 (DE3) surface and confirmed by western blotting, Enzyme-Linked Immunosorbent Assay (ELISA), and flow cytometry detection techniques.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Conclusion: The presence of HCV antigens on non-pathogen bacteria surfaces holds promise for developing safe and cost-benefit-accessible vaccines with optimal intrinsic adjuvant effects and exposure of heterologous antigens to the immune system.&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
